Akari Therapeutics Interim CFO Kameel Farag Acquires 20,452 ADS Shares Through RSU Vesting

This Form 4 filing reports that Kameel D. Farag, Interim CFO of Akari Therapeutics Plc (AKTX), acquired 20,452 American Depositary Shares (ADS) representing ordinary shares through the vesting of restricted stock units (RSUs) on June 24, 2026. The RSUs vested in full on that date, with each RSU representing the right to receive 80,000 ordinary shares. The transactions occurred at various price points ranging from $3.49 to $13.00 per share, resulting in a total post-transaction ownership of 20,452 ADS shares. The filing indicates direct ownership of these securities by the officer. This represents a significant equity acquisition by the company's interim CFO through previously granted compensation awards.